Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the effect of vitamin D supplementation on the clinical outcomes including duration and severity of rotavirus-induced gastroenteritis in children that will be admitted to the hospital. And to evaluate the anti-inflammatory effect of vitamin D on the pediatrics with rotavirus gastroenteritis by measuring inflammatory markers such as C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocytes ratio (PLR), lymphocytes to monocytes ratio (LMR) and mean platelet volume MPV.
Evaluation of effect of vitamin D supplementation on the clinical outcomes including duration and severity of rotavirus-induced gastroenteritis in children that will be admitted to the hospital. And to evaluate the anti-inflammatory effect of vitamin D on the pediatrics with rotavirus gastroenteritis by measuring inflammatory markers such as C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocytes ratio (PLR), lymphocytes to monocytes ratio (LMR) and mean platelet volume MPV.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group I (control): received standard treatment which include rehydration therapy and antipyretic the | Placebo Comparator | Group I (control): will receive standard treatment which include rehydration therapy and antipyretic therapy |
|
| Group II (Treatment) group: received vitamin D single oral dose 300000 IU for age < 1 year and dose | Experimental | Group II (Treatment) group: received vitamin D single oral dose 100000 IU for age < 1 year and dose of 300000IU for age> 1 year in addition to standard treatment. The study lasted 6 months, with follow-ups at 7-10 days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vitamin D (Cholecalciferol ) | Dietary Supplement | Group II (Treatment) group: received vitamin D single oral dose 100000 IU for age < 1 year and dose of 300000IU for age> 1 year in addition to standard treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Severity of diarrhea | severity of diarrhea will be measured by frequency of daily bowel movement | 7 days |
| Duration of diarrhea | Duration of diarrhea will be measured by days | 7 days |
| Severity of vomiting | Severity of vomiting will be measured by frequency of vomiting per day | 7 days |
| Duration of vomiting | Duration of vomiting will be measured by days | 7 days |
| Hydration state | Hydration state will be measured by score (1 fore well hydrated,2 for mild dehydration, 3 for moderate dehydration and 4 for severe dehydration) | 7 days |
| Temperature | Temperature will be measured by nominal scale (1 for febrile and 0 fir afebrile patient) | 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Measuring LMR at admission, after 4 days and after 7 days both groups. | Measuring LMR will be done by getting ratios of blood cells from CBC test | 7 days |
| C reactive protein (CRP) | CRP will be measured in mg/dl by CRP agglutination test |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AL Kadhimia pediatric hospital | Baghdad | Baghdad Governorate | 00964 | Iraq |
Participant data such as clinical outcomes, laboratory data and demographic data
in March 2026 and will be always available
Researchers will be able to access data from open access journal
Not provided
| ID | Term |
|---|---|
| D002762 | Cholecalciferol |
| ID | Term |
|---|---|
| D002782 | Cholestenes |
| D002776 | Cholestanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Standard treatment for rotavirus | Drug | Standard treatment for rotavirus which includes rehydration therapy and antipyretic therapy including sodium chloride fluid and paracetamol infusion |
|
| 7 days |
| Mean platelet volume (MPV) | Mean platelet volume (MPV) will be measured in femtoliter (fL) | 7 days |
| Measuring NLR at admission, after 4 days and after 7 days both groups. | Measuring NLR at admission, after 4 days and after 7 days both groups. | 7 days |
| Measuring PLR at admission, after 4 days and after 7 days both groups. | Measuring PLR at admission, after 4 days and after 7 days both groups. | 7 days |
| D011083 |
| Polycyclic Compounds |
| D013261 | Sterols |
| D014807 | Vitamin D |
| D012632 | Secosteroids |
| D008563 | Membrane Lipids |
| D008055 | Lipids |